COMPANY PROFILE

TreeFrog Therapeutics

Explore full profile

Stem cell company that will enable millions of patients to access the medical revolution of cell

Pessac, FranceFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Revenue $10–50M Latest reported FY

Headcount 100–500 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About TreeFrog Therapeutics

TreeFrog Therapeutics is a French biotechnology company specializing in cell therapy. The company has developed a proprietary technology called C-Stem, which enables the mass production of high-quality stem cells. This technology addresses a major challenge in the field of cell therapy, which is the ability to produce large quantities of cells for clinical and commercial use.

Read full description

The company's business model is based on developing its own pipeline of cell therapies and collaborating with other companies in the field. TreeFrog Therapeutics is currently focused on developing treatments for neurodegenerative diseases, such as Parkinson's disease, and has a pipeline of therapeutic candidates in preclinical development. The company operates in the regenerative medicine market, which is a rapidly growing segment of the healthcare industry.

TreeFrog Therapeutics serves a variety of clients, including pharmaceutical and biotechnology companies, as well as academic research institutions. The company's C-Stem technology is available for licensing, and TreeFrog Therapeutics also provides cell manufacturing services to its partners.

Source: Dealroom company data